Merck's PCSK9 Pill Shows Promise in Lowering LDL Cholesterol
Merck's oral PCSK9 inhibitor, Enlicitide, significantly reduces LDL cholesterol by up to 60% in high-risk patients already on statins, matching the efficacy of injectable treatments, according to a late-stage clinical trial.